Sunday, 14 August 2022

IQVIA collaborates AstraZeneca to support potential COVID-19 vaccine development

22 July 2020 | News

The partnership drives AZD1222 development in the US

Photo Credit: Freepik

Photo Credit: Freepik

IQVIA™, on 14 July 2020 announced its collaboration with AstraZeneca to accelerate the development of a potential new vaccine for COVID-19. This joint initiative is part of the U.S. government’s recently announced Operation Warp Speed project.

Operation Warp Speed is part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The specific IQVIA and AstraZeneca collaboration will drive faster delivery of clinical studies in the U.S. aimed at demonstrating efficacy of AstraZeneca’s potential COVID-19 vaccine, AZD1222. This initiative includes an expansive subject study, which is expected to begin enrolling participants this summer and will leverage IQVIA’s Virtual Trial solutions including Study Hub.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account